U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States

FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures

Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.

FDA SIUU Communications Q&A Guidance (Jan. 2025); 21 U.S.C. 352(a)

What is FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures?

Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties. Apply to HCP-directed reprints, guideline excerpts, emails and digital resources that discuss unapproved uses of an approved prescription drug.

US Federal

Read official source

Last reviewed: 2026-11-05

General information, not legal advice.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

email, print, digital, website, trade_publication

When does this rule take effect?

2026-10-07

What does this rule require?

Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.

How can marketing teams comply?

Apply to HCP-directed reprints, guideline excerpts, emails and digital resources that discuss unapproved uses of an approved prescription drug.

Where can I read the official source?

Read official source

Key facts

Regulatory authority
U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch)
Jurisdiction
United States
Official citation
FDA SIUU Communications Q&A Guidance (Jan. 2025); 21 U.S.C. 352(a)
Published
2026-11-16
Effective date
2026-10-07
Channel
email, print, digital, website, trade_publication
Products
Prescription Drug
Audiences
general_audience, general_adults_18plus, customers, health_professionals

Frequently asked questions

What is FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures?

Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

email, print, digital, website, trade_publication

When does this rule take effect?

2026-10-07

Request a free compliance scan of your homepage and book a time with Warrant.

Get a free homepage compliance scan